Trials / Unknown
UnknownNCT04412564
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with advanced malignant tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3101 | TQ-B3101 is a ALK inhibitor. |
Timeline
- Start date
- 2020-08-05
- Primary completion
- 2021-03-31
- Completion
- 2021-09-01
- First posted
- 2020-06-02
- Last updated
- 2020-08-18
Locations
36 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04412564. Inclusion in this directory is not an endorsement.